The study investigated how Ershiwuwei Songshi Pills, a Tibetan medicine, could protect against liver injuries caused by α-naphthalene isothiocyanate (ANIT) in rats, focusing on the FXR signaling pathway.
Rats were divided into groups, receiving either the Tibetan medicine or a control drug, UDCA, with preventive doses administered prior to inducing the liver injury.
Results showed that the Tibetan medicine significantly improved liver function by reducing specific enzyme and bilirubin levels in serum and positively influencing the expression of liver-related genes and proteins associated with cholestasis.